Back to results
US 12,565,680 B2Granted
Cancer neoantigens and their utilities in cancer vaccines and TCR-based cancer immunotherapy
AssigneeThe Methodist Hospital System
InventorsRongfu Wang, Yicheng Wang, Lili Zhang, Chen Qian
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for identifying neoantigens and using neoantigens in the use of treating cancer, as well as autoimmune diseases, where antigens causing tissue destruction.
Claims4
A composition comprising a therapeutically effective amount of one or more T cell receptor (TCR) T cells engineered to express a T cell receptor that recognize a tumor antigen and a lysine-specific histone demethylase 1 (LSD1) inhibitor that enhances the anti-tumor activity of the T cells, wherein the LSD1 inhibitor is Tranylcypromine (2-PCPA).
Dependencies are inferred from the claim text.